Press Releases

Anixa Biosciences, Inc. a biotechnology company focused on the treatment and prevention of cancer, today announced that, in partnership with Moffitt Cancer Center, it has completed treatment of the first patient cohort in the ongoing clinical trial of Anixa's novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. All three patients in the first cohort received the same dose of engineered T-cells, with no dose-limiting toxicities observed. Following the requis

 the world’s largest pharma event, held at Fira Barcelona and CPHI & PMEC India to be held at India Expo Centre, Greater Noida, Delhi NCR (November 28-30) key highlights from the CPHI pharma survey are announced. The full findings will be published at CPHI Barcelona as part of the CPHI Annual Report. The results will provide a forward-looking steer on pharma bushiness confidence in the year ahead and feature the insights from more than 250 global pharma executives. In

MediLink Therapeutics announced today that it has entered into a strategic research collaboration and worldwide license agreement with BioNTech SE (Nasdaq: BNTX, "BioNTech"), a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, on the development of a next-generation antibody-drug conjugate candidate ("ADC"), against Human Epidermal Growth Factor Receptor 3 (HER3). Under the terms of the agreement, MediLink wil

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved a global pivotal registrational Phase III study designed to evaluate a key drug candidate in Ascentage Pharma's pipeline, Bcl-2 inhibitor APG-2575 (Lisaftoclax), in combination with the Bruton's

Cerba Research, a leading global clinical trial laboratory service provider owned by Cerba HealthCare, is transforming into a multi-specialist and central laboratory company, providing research organisations with even greater access to exceptional scientific and technical teams in multiple therapeutic areas for drug and vaccine development. The company has deepened its expertise and expanded its global reach with the acquisition of Viroclinics-DDL, the global specialist in virology

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it has entered into a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio to be developed for the potential treatment of atopic dermatitis (AD) and potentially for other allergic and immunological diseases. Astria plans to develop the lead candidate, called STAR-0310, a monoclonal antibody

Ichnos Sciences, a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology, today announced that the company has entered into an exclusive worldwide licensing agreement for its OX40 antagonist monoclonal antibody portfolio with Astria Therapeutics, a biopharmaceutical company developing therapies for rare allergic and immunological diseases. With the execution of this agreement, Ichnos has successfully licensed its two assets for inflammatory an

Bayer AG announced today the opening of its first Cell Therapy Launch Facility in Berkeley, California to create the capacity to bring cell therapies to patients on a global scale. The $250 million (USD), 100,000-square-foot facility will supply the material required for late-stage clinical trials and potential commercial launch of BlueRock Therapeutics’ bemdaneprocel (BRT-DA01), an investigational cell therapy currently in evaluation for treating Parkinson’s disease. In addition,

Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, is pleased to announce that it has entered into an agreement to acquire the European rights to Duphaston® and Femoston® from Viatris Inc. Viatris retains the rights for Australia and Japan. The transaction is subject to customary regulatory and anti-trust approvals. “As we continue to strengthen our commitment to women’s health and improve our patients access to high q

Fujitsu Limited and the HPC- and AI-driven Drug Development Platform Division of the RIKEN Center for Computational Science today announced that they have developed an AI drug discovery technology that can predict structural changes of proteins from electron microscope images as a 3D density map in wide range by utilizing generative AI in January 2023. The two parties further plan to present a paper on this technology at MICCAI 2023, the top international conference in the field of medical im